Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.
CAHON: Stop hate crimes and racism
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. We are proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
Aims and scope
Articles
-
-
Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis
-
A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis
-
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies
-
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
-
Breast cancer brain metastases: the last frontier
-
COVID-19 vaccination associated severe immune thrombocytopenia
-
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
-
Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies
-
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
Editors-in-Chief
Zihai Li, The Ohio State University
Delong Liu, New York Medical College
Kongming Wu, Tongji Medical Colleg
Editor's quote (Dr. Delong Liu)
"Like our companion journal, Journal of Hematology & Oncology, Experimental Hematology & Oncology publishes on all aspects of hematology and oncology, which are closely intertwined and rapidly evolving fields. It also emphasizes basic and translational research, as well as patient-oriented research and clinical trials with ‘negative’ or preliminary results. The journal is an international platform for sharing findings in these areas and adheres to fast turnaround times."
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Springer Nature Oncology Portfolio
Discover the range of academic oncology titles at Springer Nature here.
Follow
Annual Journal Metrics
-
Speed
32 days to first decision for reviewed manuscripts only
20 days to first decision for all manuscripts
59 days from submission to acceptance
12 days from acceptance to publicationCitation Impact
5.133 - 2-year Impact Factor
3.740 - 5-year Impact Factor
0.963 - Source Normalized Impact per Paper (SNIP)
1.223 - SCImago Journal Rank (SJR)
Usage
182,093 Downloads
64 Altmetric Mentions
On the blog
-
Screening for kidney cancer in Leeds
16 April 2021
-
-
MIRRORS: robotic surgery for advanced ovarian cancer
19 February 2021
